| Literature DB >> 30653489 |
Laurent Gétaz1,2, Rosario Castro3, Pablo Zamora4, Marcelo Kramer5, Nestor Gareca6, Maria Del Carmen Torrico-Espinoza7, José Macias8, Susana Lisarazu-Velásquez9, Gloria Rodriguez10, Carola Valencia-Rivero11, Thomas Perneger12, François Chappuis1.
Abstract
BACKGROUND: Strongyloidiasis can be fatal in immunocompromised patients, but few epidemiological studies investigated the burden of this neglected tropical disease among these populations, particularly in low- and middle-income countries such as Bolivia. This study aimed to fill in this gap by estimating prevalence rate and risk factors associated with strongyloidiasis among patients at high risk of complications.Entities:
Mesh:
Year: 2019 PMID: 30653489 PMCID: PMC6353209 DOI: 10.1371/journal.pntd.0007028
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Clinical characteristics and immunosuppressive treatment of patients according to pathology groups.
| All patients | HIV | Rheumatology | Oncology | Hematology | |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| 890 (77.3) | 212 (61.6) | 293 (87.7) | 300 (80.9) | 85 (83.3) | |
| 261 (22.6) | 128 (38.4) | 40 (12.3) | 71 (19.1) | 17 (16.7) | |
| 243 (21.1) | 1 (0.3) | 204 (61.1) | 23 (6.2) | 15 (14.7) | |
| 908 (78.9) | 343 (99.7) | 130 (38.9) | 348 (93.8) | 87 (85.3) | |
| 249 (21.6) | 0 (0) | 170 (50.9) | 51 (13.7) | 28 (27.5) | |
| 902 (78.4) | 344 (100) | 164 (49.1) | 320 (86.3) | 74 (72.5) | |
| 52 (4.5) | 23 (6.7) | 4 (1.2) | 20 (5.4) | 5 (4.9) | |
| 1099 (94.5) | 321 (93.3) | 330 (98.8) | 351 (94.6) | 97 (95.1) | |
| 109 (9.5) | 44 (12.8) | 28 (8.4) | 26 (7.1) | 11 (10.8) | |
| 1042 (89.5) | 300 (87.2) | 306 (91.6) | 345 (92.9) | 91 (89.2 | |
| 425 (36.9) | 134 (39.0) | 83 (24.9) | 174 (46.9) | 34 (33.3) | |
| 726 (63.1) | 210 (61.0) | 251 (75.1) | 197 (53.1) | 68 (66.7) | |
| 344 (30.8) | 129 (37.5) | 76 (22.8) | 108 (29.1) | 41 (40.2) | |
| 797 (69.2) | 215 (62.5) | 258 (77.2) | 263 (70.9) | 61 (59.8) |
aRheumatology: methotrexate (n = 115); leflunomide (n = 22); azathioprine (n = 20); leflunomide + methotrexate (n = 8); azathoprine + methotrexate (n = 1); leflunomide + rituximab (n = 1); mycophenolate (n = 1); cyclophosphamide (n = 1); adalimumab (n = 1); Oncology: chemotherapy (n = 51); Hematology: chemotherapy (n = 28)
bAscaris lumbricoides: 1.6% (n = 18/1151), Hymenolepis nana 1.3% (n = 15/1151), Ancylostoma sp 0.9% (n = 10/1151), Trichuris trichiuria 0.5% (n = 6/1151), Enterobius vermicularis: 0.3% (n = 4/1151)
cGiardia lamblia: 4.4% (n = 44/1151), Entamoeba histolytica/dispar: 3.7% (n = 43/1151), Cryptosporidium sp: 1.5% (n = 17/1151), Isospora belli: 0.4% (n = 5/1151).
Socio-demographic, life style and clinical factors associated with S. stercoralis in bivariate analysis, according to coproparasitological and serological results.
| Characteristics | Positive coproparasitology (n = 88) | Positive serology | |||||
|---|---|---|---|---|---|---|---|
| n | n (%) | OR (95% CI) | p | n (%) | OR (95% CI) | p | |
| | 573 | 51 (8.9) | 1.4 (0.9–2.2) | 0.11 | 126 (22.0) | 0.9 (0.7–1.2) | 0.40 |
| | 578 | 37 (6.4) | (ref) | 139 (24.0) | (ref) | ||
| | 384 | 42 (10.9) | 99 (25.8) | ||||
| | 540 | 39 (7.2) | 127 (23.5) | ||||
| | 227 | 7 (3.1) | (ref) | 39 (17.2) | (ref) | ||
| | 377 | 40 (10.6) | 89 (23.6) | 1.1 (0.8–1.4) | 0.74 | ||
| | 774 | 48 (6.2) | (ref) | 176 (22.7) | (ref) | ||
| | 400 | 55 (13.8) | 126 (31.5) | ||||
| | 517 | 29 (5.6) | 105 (20.3) | 1.5 (1.0–2.3) | |||
| | 234 | 4 (1.7) | (ref) | 34 (14.5) | (ref) | ||
| 172 | 22 (12.8) | 48 (27.9) | 1.4 (0.9–2.0) | 0.097 | |||
| 976 | 66 (6.8) | (ref) | 216 (22.1) | (ref) | |||
| 781 | 68 (8.7) | 195 (25.0) | |||||
| 306 | 15 (4.9) | (ref) | 59 (19.3) | (ref) | |||
| 261 | 29 (11.1) | 63 (24.1) | 1.1 (0.8–1.5) | 0.63 | |||
| 889 | 56 (6.3) | (ref) | 202 (22.7) | (ref) | |||
| 243 | 10 (4.1) | (ref) | 52 (21.4) | (ref) | 0.50 | ||
| 908 | 78 (8.6) | 213 (23.5) | 1.1 (0.8–1.6) | ||||
| 249 | 15 (6.0) | (ref) | 0.28 | 52 (20.9) | (ref) | 0.36 | |
| 902 | 73 (8.1) | 1.4 (0.8–2.5) | 213 (23.5) | 1.2 (0.8–1.7) | |||
| CD4+ count (cells/ml) | |||||||
| HIV<300 | 171 | 31 (18.1) | 43 (25.2) | 1.0 (0.7–1.4) | 0.98 | ||
| HIV≥300 or HIV not known | 880 | 57 (6.5) | (ref) | 222 (25.2) | (ref) | ||
| 52 | 11 (21.2) | 17 (32.7) | 1.7 (0.9–3.0 | 0.09 | |||
| 1099 | 77 (7.0) | (ref) | 248 (22.6) | (ref) | |||
| 109 | 10 (9.2) | 1.2 (0.6–2.4) | 0.55 | 19 (17.4) | 0.7 (0.4–1.2) | 0.14 | |
| 1042 | 78 (7.5) | (ref) | 246 (23.6) | (ref) | |||
| 354 | 38 (10.7) | 87 (24.6) | 1.1 (0.8–1.5) | 0.4 | |||
| 797 | 50 (6.3) | (ref) | 178 (22.3) | (ref) | |||
| 425 | 45 (10.6) | 108 (25.4) | 1.2 (0.9–1.6) | 0.14 | |||
| 726 | 43 (5.9) | (ref) | 157 (21.6) | (ref) | |||
aSee
S. stercoralis larvae in direct smear examination, formalin-gasoline sedimentation technique, agar plate culture and modified Baermann technique of two stool samples*.
| DSE | FGST | APC | MBT | Combined 4 methods | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| Cumulative result after examination of | ||||||||||
| 1 stool sample | 20 | 2.5 | 17 | 2.1 | 48 | 6.0 | 46 | 5.7 | 53 | 6.6 |
| 2 stool samples | 29 | 3.6 | 31 | 3.9 | 61 | 7.6 | 64 | 8.0 | 72 | 9.0 |
| Sensitivity | 29/72 | 40.3 | 31/72 | 43.1 | 61/72 | 84.7 | 64/72 | 88.9 | ||
| Sensitivity | 37/144 | 25.7 | 39/144 | 27.1 | 97/144 | 67.4 | 100/144 | 69.4 | ||
*stool results processed in CENETROP laboratory were not included (see methods section)
**sensitivity among people with S. stercoralis larvae detected with at least one coproparasitological technique (the global sensitivity of each test is not computable due to the lack of gold standard for the diagnosis of S. stercoralis)
DSE = direct smear examination, FGST = formalin-gasoline sedimentation technique, APC = agar plate culture, MBT = modified Baermann technique
Socio-demographic and life style characteristics of patients according to pathology groups.
| Characteristics | All patients | HIV | Rheumatology | Oncology | Hematology |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| 46.4 (14.7) | 38.1 (12.1) | 50.4 (15.0) | 50.4 (13.0) | 46.6 (16.2) | |
| 377 (32.8) | 220 (64.0) | 42 (12.6) | 60 (16.2) | 55 (53.9) | |
| 774 (67.2) | 124 (36.0) | 292 (87.4) | 311 (83.8) | 47 (46.1) | |
| 400 (34.8) | 116 (33.7) | 77 (23.1) | 171 (46.1) | 36 (35.3) | |
| 453 (39.3) | 140 (40.7) | 141 (42.2) | 138 (37.2) | 34 (33.3) | |
| 64 (5.6) | 26 (7.6) | 23 (6.9) | 14 (3.8) | 1 (1.0) | |
| 234 (20.3) | 62 (18.0) | 93 (27.8) | 48 (12.9) | 31 (30.4) | |
| 172 (15.0) | 59 (17.2) | 41 (12.3) | 57 (15.4) | 15 (15.0) | |
| 976 (85.0) | 285 (82.8) | 293 (87.7) | 313 (84.6) | 85 (85.0) | |
| 573 (49.8) | 168 (48.8) | 163 (48.8) | 169 (45.6%) | 73 (71.6) | |
| 578 (50.2) | 176 (51.2) | 171 (51.2) | 202 (54.4) | 29 (28.4) | |
| 306 (26.6) | 97 (29.4) | 102 (33.1) | 72 (20.5) | 35 (36.1) | |
| 781 (73.4) | 233 (70.6) | 206 (66.9) | 280 (79.5) | 62 (63.9) |
aMissing data: living area (n = 3), walking without shoes when in tropical or subtropical area (n = 64:participants from Cochabamba who never lived or travelled to tropical or subtropical area)
SD = standard deviation
Socio-demographic and life style characteristics associated with S. stercoralis in multivariate analysis, according to coproparasitological and serological results.
| Positive | Positive | |||
|---|---|---|---|---|
| Adjusted OR (95% CI) | p | Adjusted OR | p | |
| 2.0 (1.2–3.4) | 1.0 (0.7–1.5) | 0.90 | ||
| 0.7 (0.6–0.8) | 0.8 (0.8–0.9) | |||
| 1.5 (0.9–2.6) | 0.11 | 1.1 (0.8–1.6) | 0.44 | |
| 13.6 (4.6–39.8) | 3.1 (2.0–4.9) | |||
| 1.6 (0.9–2.7) | 0.12 | 1.2 (0.8–1.8) | 0.27 | |
| 2.6 (1.3–5.0) | 1.4 (0.9–2.0) | 0.11 | ||
| 1.7 (1.0–2.9) | 1.0 (0.7–1.4) | 0.97 | ||
| 1.1 (0.5–2.4) | 0.76 | 1.2 (0.8–1.8) | 0.31 | |
| 2.1 (1.2–3.8) | 0.9 (0.6–1.4) | 0.74 | ||
*reference group indicated in Table 3
OR: odds ratio; CI: confidence interval